Leállítva1/2. fázis
Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC
A legfontosabb adatok
- Ki végzi
- Galera Therapeutics, Inc.
- Hol
- Cleveland, Columbus, Dallas, Durham, Greeley, Iowa City, Loveland, Spartanburg és Spokane (Egyesült Államok)Mind a 10 helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Fázis
- 1/2. fázis
- Résztvevők
- 47 fő vett részt
- Kezdés
- 2020. okt. 18.
- Befejezés
- 2023. nov. 28.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- GC4711 +SBRT
- Placebo +SBRT
- A regiszteradat frissítve
- 2024. április 30.
- Miért állt le
- Development GC4711 was halted after the lead study in pancreatic cancer was stopped early due to meeting the requirements of a futility analysis
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 19 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female subjects at least 18 years of age
- Ability to understand and the willingness to sign a written informed consent
- Histological or biopsy proven NSCLC
- ECOG performance status of 0-3
- Node negative (T1 to T3N0M0), centrally located (within 2cm in all directions around the proximal bronchial tree, including ultra-central tumors, abutting the bronchial tree or trachea) or large (>1-7cm) Non-Small Cell Lung Cancer (NSCLC), judged acceptable for SBRT by the treating Investigator
- Adequate end-organ function, based on routine clinical and laboratory workup:; ANC >1,000 cells/µl, Platelets ≥ 75,000 cells/µl, Hemoglobin ≥ 7.0 g/dl; Serum creatinine ≤ 2 x ULN or calculated creatinine clearance ≥ 30 ml/min; Total bilirubin ≤ 1.5 x ULN (or direct bilirubin below the ULN), AST and ALT ≤ 2.5 x ULN
- Males and females of must agree to use effective contraception starting prior to the first day of treatment and continuing after the last dose of GC4711/Placebo for 30 days (females) and 90 days (males)
Ki nem vehet részt
- Prior treatment with immunotherapy within 3 months prior to Day 1 dosing
- Prior intra-thoracic radiotherapy or surgery with substantial overlap to planned radiation fields as determined by the treating radiation oncologist
- Subjects not recovered/controlled from prior treatment-related (chemotherapy or targeted therapy) toxicities judged by treating physician
- Participation in other clinical trials actively testing new anti-cancer treatments, unless previously written approval is provided by the Sponsor
- Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure
- Subjects with confirmed nodal and/or distant disease(including brain), according standard workup by local investigator
- Uncontrolled malignancy other than lung cancer that requires active treatment or is deemed by the treating physicians to be likely to affect the subject's survival duration
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to GC4711
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements
- Any other conditions that, in the Investigator's opinion, might indicate the subject to be unsuitable for the study
- Subjects with peripheral lesions 1cm or smaller
- Female subjects who are pregnant or breastfeeding
Helyszínek itt: Egyesült Államok
- University Hospitals Cleveland Medical Center*Cleveland, Egyesült Államok
- IACT HealthColumbus, Egyesült Államok
- Parkland Health and Hospital SystemDallas, Egyesült Államok
- The University of Texas Southwestern Medical CenterDallas, Egyesült Államok
- Duke University Medical CenterDurham, Egyesült Államok
- Banner MD Anderson Cancer Center at NCMCGreeley, Egyesült Államok
- University of Iowa Hospitals and ClinicsIowa City, Egyesült Államok
- Banner McKee Medical CenterLoveland, Egyesült Államok
- Gibbs Cancer Center & Research InstituteSpartanburg, Egyesült Államok
- Cancer Care NorthwestSpokane, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
GTI-4711-101 is a Phase I/II study of the safety of GC4711, its effect on in-field tumor response and its potential to reduce radiation-related pulmonary injury due to SBRT for lymph node negative (T1 to T3N0M0) peripheral or central localized (within 2cm of the proximal bronchial tree) NSCLC.
A teljes eredeti leírásKevesebb
After an open-label, Phase 1, safety cohort of 5 subjects has been completed, a randomized, placebo-controlled Phase 2 portion of 66 subjects will be conducted.
A vizsgálat 3 csoportja
- Phase 1 GC4711 + SBRTA vizsgált kezelés
Kezelés: GC4711 +SBRT
- Phase 2 Placebo + SBRTPlacebo, összehasonlításként
Kezelés: Placebo +SBRT
- Phase 2 GC4711 +SBRTA vizsgált kezelés
Kezelés: GC4711 +SBRT
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- GRECO-1: Phase I/II, Randomized, Placebo-Controlled Study of Stereotactic Body Radiation Therapy (SBRT) and GC4711 for Centrally Located or Large, Node-Negative Non-Small Cell Lung Cancer (NSCLC)
- A regiszteradat frissítve
- 2024. április 30.